n-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine has been researched along with haloperidol in 1 studies
| Studies (n-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine) | Trials (n-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine) | Recent Studies (post-2010) (n-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine) | Studies (haloperidol) | Trials (haloperidol) | Recent Studies (post-2010) (haloperidol) |
|---|---|---|---|---|---|
| 37 | 1 | 1 | 20,330 | 1,753 | 3,294 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kovar, KA; Mayerhofer, A; Meyer, A; Schmidt, WJ | 1 |
1 other study(ies) available for n-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine and haloperidol
| Article | Year |
|---|---|
Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect?
Topics: 3,4-Methylenedioxyamphetamine; Adrenergic Uptake Inhibitors; Animals; Catalepsy; Dopamine Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; N-Methyl-3,4-methylenedioxyamphetamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 2002 |